Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5829662 | 1.00 | LMNA (0.38) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL3418340 | 0.98 | LMNA (0.37) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Alcohol SCHEMBL15066415 | 0.97 | LMNA (0.35) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL8325036 | 0.95 | LMNA (0.34) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL6573573 | 0.95 | LMNA (0.34) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Fructose SCHEMBL11151878 | 0.90 | CYP2C9 (0.34) | LMNAL3MBTL1PDE4A | |
| SCHEMBL18341352 | 0.87 | AKR1B1 (0.33) | AKR1B1 | |
| SCHEMBL17844291 | 0.87 | — | — | |
| SCHEMBL2722434 | 0.87 | LMNA (0.35) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL4274437 | 0.87 | LMNA (0.35) | LMNAL3MBTL1PDE4ATDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241957-A1 | INTRA-ERYTHROCYTE DEXAMETHASONE FOR TREATMENT OF ATAXIA-TELANGIECTASIA | QUINCE THERAPEUTICS S.P.A. (IT) | 2025-07-31 | — | — | US | claimed |
| US-12311059-B2 | Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes | QUINCE THERAPEUTICS S.P.A. (IT) | 2025-05-27 | — | — | US | claimed |
| US-20060281159-A1 | Method for sustained microbial production of hydrogen gas in a bioreactor | DIZ HARRY R | 2006-12-14 | — | — | US | claimed |
| US-5076273-A | Collecting a body fluid in dermal concentration patch; complexing analyte with immobilized binding partner; perspiration; non-invasive | SUDOR PARTNERS (US) | 1991-12-31 | — | — | US | claimed |
| CN-122038274-A | Method for inducing differentiation and maturation of alveolar organoids and application thereof | 广州国家实验室 | 2026-05-15 | — | — | CN | disclosed |
| CN-122038284-A | Method for inducing differentiation of anterior foregut endoderm cells to form lung progenitor cells and application thereof | 广州国家实验室 | 2026-05-15 | — | — | CN | disclosed |
| US-20260130895-A1 | METABOLISM ENHANCING COMPOSITIONS | Red Mountain Med Spa, LLC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4281538-B1 | APPARATUS, SYSTEMS, AND METHODS FOR PREPARING AN OUTPUT SAMPLE WITH AERATION | AVAILS MED INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12551470-B2 | Metabolism enhancing compositions | Red Mountain Med Spa, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-12522854-B2 | Systems, devices and methods for determining most probable number in biological sample analysis | ANCERA, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4350323-B1 | METHODS FOR PREPARING AN OUTPUT SAMPLE COMPRISING A DEFINED CONCENTRATION OF AN INFECTIOUS AGENT FOR DOWNSTREAM TESTING | AVAILS MED INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250325702-A1 | COMPOSITIONS AND METHODS FOR EDITING A TRANSTHYRETIN GENE | BEAM THERAPEUTICS INC. (US) | 2025-10-23 | — | — | US | disclosed |
| WO-1998051277-A1 | MEDICAL USES OF PYRUVATES | CASE WESTERN RESERVE UNIVERSITY (US) | 1998-11-19 | — | — | WO | disclosed |
| EP-0543867-B1 | METHOD AND APPARATUS FOR DETERMINATION OF CHEMICAL SPECIES IN BODY FLUID | SUDOR PARTNERS (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0433382-B1 | METHOD AND APPARATUS FOR CHEMICAL SPECIES DETERMINATION | SCHOENDORFER DONALD W (US) | 1995-11-08 | — | — | EP | disclosed |
| WO-1992021234-A1 | COMPOSITION AND METHOD FOR CULTURING AND FREEZING CELLS AND TISSUES | VETREPHARM, INC. (CA) | 1992-12-10 | — | — | WO | disclosed |
| EP-0337003-B1 | USE OF FRUCTOSE-1,6-DIPHOSPHATE IN THE TREATMENT OF ACUTE ALCOHOLIC INTOXICATION AND CHRONIC ETHYLISM, AND RELATED PHARMACEUTICAL COMPOSITIONS | BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A. (IT) | 1992-09-30 | — | — | EP | disclosed |
| US-5102783-A | Using hyaluronic acid acid | VETREPHARM, INC. (CA) | 1992-04-07 | — | — | US | disclosed |
| EP-0337003-A2 | Use of fructose-1,6-diphosphate in the treatment of acute alcoholic intoxication and chronic ethylism, and related pharmaceutical compositions | BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A. (IT) | 1989-10-18 | — | — | EP | disclosed |
| US-4870057-A | Use of fructose-1,6-diphosphate in the treatment of acute alcoholic intoxication and chronic ethylism, and related pharmaceutical compositions | BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A. (IT) | 1989-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325702-A1 | COMPOSITIONS AND METHODS FOR EDITING A TRANSTHYRETIN GENE | TTR, TTN, HTT | LMNA 81/4885L3MBTL1 413/4885PDE4A 3522/4885 |
| US-20260130895-A1 | METABOLISM ENHANCING COMPOSITIONS | GYS2, SLC19A1, SLC19A2 | LMNA 1425/4885L3MBTL1 2259/4885PDE4A 2639/4885 |
| US-12551470-B2 | Metabolism enhancing compositions | BHMT, SLC19A2, GYS2 | LMNA 1513/4885L3MBTL1 1677/4885PDE4A 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.